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Abstract: Schizoaffective disorder is characterized by the presence of symptoms of both 
schizophrenia and a major mood disorder. The coexistence of these symptoms can be difficult to 
manage, and these patients are generally treated with antipsychotics as well as mood stabilizers 
and/or antidepressants. Additionally, no established treatment guidelines exist for this disorder. 
This review describes the combined results of two international, double-blind, placebo-controlled 
clinical studies of paliperidone extended-release (ER), an atypical antipsychotic recently 
approved in the US for the treatment of schizoaffective disorder. Subjects in these six-week 
trials were aged 18–65 years, had a diagnosis of schizoaffective disorder based on the Struc-
tural Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition) Disorders, and were experiencing an acute exacerbation. The subjects from these 
studies had significant symptomatology as evidenced by a mean (standard deviation) baseline 
Positive and Negative Syndrome Scale total score of 92.8 (13.0). Based on Young Mania Rating 
Scale and/or a 21-item Hamilton Rating Scale for Depression score of $16 at baseline, 79.5% 
and 66.9% of subjects presented with prominent manic and depressive symptoms, respectively, 
and 46.4% presented with mixed symptoms. Approximately half (45%) of subjects were taking 
adjunctive mood stabilizers and/or antidepressants. Paliperidone ER was found to be effec-
tive in improving psychotic and mood symptoms in these subjects. Paliperidone ER was also 
effective as monotherapy or adjunctive to mood stabilizers and/or antidepressants for subjects 
with prominent manic, depressive, or mixed symptoms at baseline. No new tolerability signals 
were observed in this population. To the best of our awareness, these pooled data provide the 
largest data set of patients with schizoaffective disorder, and extend our knowledge of disease 
characteristics and treatment response.
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Introduction
The term “schizoaffective”, used to describe patients with concurrent schizophrenic 
and mood symptoms, was first introduced more than 75 years ago.1 Diagnosis of 
schizoaffective disorder requires that patients experience an uninterrupted period 
of illness with concurrent psychotic and mood symptoms. The psychotic symptoms 
must be present without any prominent mood symptoms for at least two weeks, yet 
mood episodes must represent a substantial portion of the total duration of illness. 
Patients with schizoaffective disorder are further classified as having the bipolar or 
depressive type (Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 
[DSM-IV]). Epidemiologic data suggest that schizoaffective disorder is about one 
third as common as schizophrenia, with a lifetime prevalence of 0.3%, compared with 
0.9% for schizophrenia,2 and such patients are regularly encountered in   psychiatric Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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clinic populations. A recent cross-national study found that 
nearly one third of a globally diverse population of patients 
with symptoms of psychosis who visited psychiatric settings 
had schizoaffective disorder.3 However, when patients with 
mental illness are characterized by their need for inpatient 
psychiatric care, those with a diagnosis of schizophrenia 
and schizoaffective disorder are almost equally represented,4 
suggesting that patients with schizoaffective disorder may 
be more disabled by their illness and consume a dispropor-
tionately large share of available inpatient mental health 
resources.
Characteristics of the schizoaffective 
disorder population
Compared with the large number of clinical trials for the treat-
ment of schizophrenia and mood disorders, fewer randomized 
studies have been conducted for schizoaffective disorder.5–10 
As such, the demographic and clinical characteristics of the 
schizoaffective population are not fully understood. Cheniaux 
and coworkers have suggested that some aspects of schizoaf-
fective disorder, such as the female-to-male gender ratio, age 
of illness onset, total number of episodes, deficits in cogni-
tion, and response to treatment, lie midrange in a spectrum 
between schizophrenia and mood disorders.11 The number of 
hospitalizations and the number of suicide attempts, however, 
are higher among those with schizoaffective disorder than in 
those with either schizophrenia or mood disorder.11
A study comparing patients with schizophrenia and 
patients with schizoaffective disorder (matched for intel-
ligence quotient, education, length of illness, and attention 
span) found that those with schizoaffective disorder had a 
less marked negative syndrome and less social avoidance 
but higher levels of depression and guilt.12 Patients with 
schizoaffective disorder were also more cognitively intact, 
had shorter inpatient stays, and had a higher prevalence of 
substance abuse in their families compared with those who 
had schizophrenia.12 A recent analysis of a large Medicaid 
database found that patients with schizoaffective disorder 
were significantly younger, more likely to be female, and 
more likely to be white, Hispanic, or of other non-African 
American race or ethnicity compared with patients with 
schizophrenia.13 Patients with schizoaffective disorder also 
were significantly more likely to receive concomitant treat-
ment for substance use or for an anxiety, depressive, bipolar, 
or other mental disorder, and significantly more likely to 
be treated with mood stabilizers, antidepressants, and anxi-
olytics.13 In addition to distinctions based on demographic 
and clinical characteristics, emerging molecular genetic 
analyses have suggested that schizoaffective disorder may 
have distinctive genetic risk factors compared with other 
psychiatric disorders.14–16
Treatment strategies
Coexistent psychotic and prominent affective symptoms can 
be difficult to address, and management is complicated by the 
variability in clinical presentations. A combination of medica-
tions and psychotherapy is typically required for these patients, 
yet there are no established treatment guidelines. Atypical 
antipsychotics have mood-stabilizing properties in addition 
to antipsychotic efficacy,17–19 and thus have the potential to 
be central in the pharmacologic treatment of schizoaffective 
disorder. Several small or open-label studies with risperidone 
in schizoaffective disorder have shown positive results.7,20–22 
A post hoc analysis of a schizoaffective subpopulation from 
a comparative study of olanzapine and haloperidol found 
greater benefits from olanzapine in measures of psychosis 
and depression, although more improvement was seen in those 
diagnosed with the bipolar type than the depressive type of 
illness.23 Similarly, two additional post hoc analyses of sub-
populations from placebo-controlled studies of ziprasidone 
and aripiprazole suggested that these agents were efficacious 
in patients with schizoaffective disorder.24,25
To manage the affective and psychotic symptoms, many 
patients with schizoaffective disorder also receive adjunctive 
treatment with mood stabilizers and/or antidepressants.26–28 
A recent Medicaid prescription claims database found that 
approximately one half of those with schizoaffective disorder 
were prescribed an antipsychotic plus a mood stabilizer or 
an antipsychotic plus an antidepressant.13 A study of hos-
pitalized patients with schizoaffective disorder in the US 
determined that antipsychotics and mood stabilizers and/or 
antidepressants were prescribed together in 87% of cases.28 
A recent multinational study found that antipsychotics alone 
was prescribed for 33.9% of patients with schizoaffective 
disorder, whereas 23.1% were taking an antipsychotic plus 
a mood stabilizer, 27.7% were taking an antipsychotic plus 
an antidepressant, and 7.7% were taking an antipsychotic 
plus a mood stabilizer and an antidepressant.3 However, the 
benefits and risks of atypical antipsychotics administered 
alone or in combination with other treatments have not 
been established.
Paliperidone extended-release  
for schizoaffective disorder
Two large, international, double-blind, placebo-  controlled, ran-
domized, six-week studies with paliperidone   extended-release Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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(ER) were conducted for schizoaffective disorder.29,30 Pali-
peridone ER is the first agent approved by the US Food and 
Drug Administration and several other countries (Australia, 
Brazil, New Zealand, and Philippines) to treat patients with 
schizoaffective disorder, both as monotherapy and as adjunc-
tive therapy with mood stabilizers and/or antidepressants.31 
In contrast with other antipsychotics, paliperidone ER 
undergoes limited hepatic metabolism and is therefore less 
likely to cause hepatically mediated drug–drug interactions 
in patients receiving multiple medications.32–34 This review of 
pooled data from the combined studies covers the largest data 
set of patients with schizoaffective disorder from random-
ized controlled trials to date, and provides insights into the 
characteristics and treatment responses of this understudied 
population.
Description of the studies
Subjects in these studies were aged 18–65 years, with a 
diagnosis of schizoaffective disorder based on the Structured 
Clinical Interview for DSM-IV Disorders (SCID). All were 
experiencing an acute exacerbation of illness as evidenced 
by a Positive and Negative Syndrome Scale (PANSS)35 total 
score $ 60 and a score $ 4 on at least two of the PANSS items 
for hostility, excitement, tension, uncooperativeness, and poor 
impulse control. Prominent mood symptoms were reflected 
in a score $ 16 on the Young Mania Rating Scale (YMRS)36 
and/or the 21-item Hamilton Rating Scale for Depression 
(HAM-D-21).37 In the first study, subjects received fixed 
dosages of paliperidone ER, ie, either the higher dosage 
(12 mg/day, with the option to reduce to 9 mg/day) or the 
lower dosage (6 mg/day, with the option to reduce to 3 mg/
day).29 In the second study, paliperidone ER was flexibly 
dosed, beginning at a dosage of 6 mg/day, with a range of 
3 to 12 mg/day.30 For both studies, any dosing changes had 
to occur within the first 15 days. Subjects receiving stable 
regimens of mood stabilizers and/or antidepressants were 
permitted to continue their ongoing treatment to allow the 
study of paliperidone ER either as monotherapy or as an 
adjunct to mood stabilizers and/or antidepressants.
Change in PANSS total score from baseline to endpoint 
was the primary outcome measure for both studies. Second-
ary efficacy measures were changes from baseline to endpoint 
for the Clinical Global Impressions of Severity for Schizo-
affective Disorder (CGI-S-SCA),38 PANSS factor scores,39 
a composite response ($30% improvement in PANSS total 
score and Clinical Global Impressions of Change for Schizo-
affective Disorder [CGI-C-SCA] of 1 or 2 [much or very 
much improved]), and the YMRS and HAM-D-21 scales. 
Safety assessments included adverse event reporting, 
clinical laboratory tests (including prolactin levels), and 
assessment of movement disorders with the Simpson-Angus 
Scale (SAS), Barnes Akathisia Scale (BAS), and Abnormal 
Involuntary Movement Scale (AIMS).40–42
Randomization for both studies was stratified by center 
and by treatment with concomitant medications (with or 
without mood stabilizers and/or antidepressants). Data from 
the two schizoaffective studies were integrated (paliperidone 
ER versus placebo) for all statistical analyses. Efficacy 
was analyzed using the intent-to-treat analysis set, which 
included all randomized subjects who received $1 dose of 
study medication and had a baseline and $1 postbaseline 
PANSS assessment. The safety population included random-
ized subjects who received $1 dose of study medication. For 
each continuous parameter, treatment group differences were 
analyzed using separate analysis-of-covariance (ANCOVA) 
models with treatment, protocol, country-within-protocol, 
concomitant medication stratum as fixed-effect design 
factors, and baseline score as a covariate. To assess con-
sistency of treatment effect within each subgroup, separate 
ANCOVA models were fit. A Forest plot by subgroups was 
generated showing least-squares mean estimates and 95% 
confidence intervals (CIs) for pairwise differences between 
paliperidone ER and placebo at week 6 last-observation-
carried-forward (LOCF) endpoint. Change from baseline 
in efficacy measures (observed case) was also analyzed 
using a repeated-measures mixed-effects linear model. This 
model included baseline PANSS total score as a covariate; 
treatment, protocol, country-within-protocol, concomitant 
medication stratum, and time (scheduled assessment visits 
on day 4 and at weeks 1, 2, 3, 4, and 6) as factors; and the 
interaction between time and treatment. The correlation 
of the repeated measures is modeled with an unstructured 
covariance matrix. Between-group differences in percentage 
of subjects who met the composite response were evaluated 
using Fisher’s exact test. Effect sizes were calculated using 
Cohen’s d methodology. Relative risks (RRs) and their 
corresponding 95% CIs were calculated for adverse events 
with $5% incidence for paliperidone ER or placebo. RR 
analyses were considered potentially significant (P = 0.05) 
when the 95% CIs did not include 1. No adjustments were 
made for multiplicity.
Population characteristics
A total of 627 randomized subjects were in the pooled 
analysis (Figure 1). In the intent-to-treat analysis set 
(n = 614), 414 subjects received paliperidone ER and 200 Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Randomized population
(N = 627)
Paliperidone ER
(n = 425)
Paliperidone ER
(n = 420)
Paliperidone ER
(n = 414)
Placebo
(n = 202)
Placebo
(n = 202)
Placebo
(n = 200)
Safety
analysis set
(n = 622)
Intent-to-treat
analysis set
(n = 614)
Completed the study: n = 283 (67%)
Discontinued: n = 142 (33%)
• Lack of efficacy: n = 43 (10%)
• Subject withdrew consent: n = 41 (10%)
• Adverse event: n = 29 (7%)
• Lost to follow-up: n = 19 (4%)
• Other: n = 10 (2%)
Completed the study: n = 115 (57%)
Discontinued: n = 87 (43%)
• Lack of efficacy: n = 38 (19%)
• Subject withdrew consent: n = 22 (11%)
• Adverse event: n = 15 (7%)
• Lost to follow-up: n = 10 (5%)
• Other: n = 2 (1%)
Figure 1 Study flow diagram. 
Abbreviation: eR, extended-release.
received placebo. The mean (standard deviation [SD]) age 
of the combined population was 37.4 (9.9) years (Table 1). 
In contrast with the male-to-female ratio of patients with 
  schizoaffective disorder in the literature, but typical of 
the ratio among   subjects included in clinical studies, 
there were more male than female subjects. The majority 
(90.9%) of subjects had a chart diagnosis of schizoaffec-
tive disorder prior to screening, and more subjects were 
diagnosed with the bipolar type than the depressive type. 
The mean age at first schizoaffective disorder diagnosis 
was approximately six years later than the age at first 
psychiatric diagnosis, which was consistent with other 
observations that the diagnosis emerges over time.43 Sub-
jects had received various other previous diagnoses, with 
schizophrenia being the most common. Nearly one third 
of subjects had attempted suicide; one half of this group 
of subjects had made two or more suicide attempts. Mean 
baseline scores for the PANSS total, YMRS, and HAM-D-
21 scales indicated that subjects had significant symptoms. 
Two hundred and seventy-five subjects (45%) were receiv-
ing adjunctive mood stabilizers and/or antidepressants at 
baseline and continued these medications during the study; 
69% were taking a mood stabilizer, and 49% were taking an 
antidepressant. Valproic acid was the most frequently used 
mood stabilizer; the most frequently used antidepressants 
were escitalopram, sertraline, and venlafaxine (Table 2). 
Also, 14% of subjects in the total population were using 
medications for extrapyramidal symptoms, and 50% were 
using nonbenzodiazepine hypnotics and anxiolytics.
The studies were designed to include dosages from 3 
to 12 mg/day, based on the recommended dose range for 
schizophrenia.31 The mean (SD) modal dosage of paliperi-
done ER in the combined studies was 8.6 (2.8) mg/day. 
Sixty-seven percent of subjects receiving paliperidone ER 
and 57% of those receiving placebo completed the study. 
The most common cause for discontinuation was lack of 
efficacy for 10% of the paliperidone ER subjects and 19% 
for the placebo subjects (Figure 1).
Efficacy
The PANSS total score improved significantly more with 
paliperidone ER than with placebo from day 4 through to Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Table 1 Baseline demographics and clinical characteristics in two studies of paliperidone eR for schizoaffective disorder (intent-to-treat 
analysis set)
Parameter Paliperidone ER (n = 414) Placebo (n = 200) Overall (n = 614)
Age, y, mean (SD) 37.5 (9.7) 37.2 (10.3) 37.4 (9.9)
Sex, n (%)
Male 250 (60.4) 121 (60.5) 371 (60.4)
Female 164 (39.6) 79 (39.5) 243 (39.6)
Race, n (%)
Caucasian 200 (48.3) 100 (50.0) 300 (48.9)
African American 81 (19.6) 37 (18.5) 118 (19.2)
Asian 129 (31.2) 63 (31.5) 192 (31.3)
Other 4 (1.0) 0 (0) 4 (1.0)
BMi, kg/m2, mean (SD) 27.2 (7.3) 27.9 (7.6) 27.5 (7.4)
Baseline mood stabilizers or antidepressants, n (%) 186 (44.9) 89 (44.5) 275 (44.8)
Age at first psychiatric diagnosis, y, mean (SD) 25.1 (8.9) 25.4 (10.1) 25.2 (9.3)
n = 408 n = 195 n = 603
Age at first SCA diagnosis, y,  31.5 (10.1) 32.0 (10.4) 31.7 (10.2)
mean (SD)
Prior diagnoses, n (%)a
Schizophrenia 194 (46.9) 96 (48.0) 290 (47.2)
Bipolar disorder 119 (28.7) 71 (35.5) 190 (30.9)
Depression 72 (17.4) 40 (20.0) 112 (18.2)
SCA diagnosis prior to screening,  n = 408 n = 195 n = 603
n (%) 366 (89.7) 182 (93.3) 548 (90.9)
SCA disorder type, n (%) n = 411 n = 200 n = 611
Bipolar 288 (70.0) 133 (67.0) 421 (68.9)
Depressive 123 (30.0) 67 (34.0) 190 (31.1)
n = 409 n = 196 n = 605
Total psychiatric hospitalizations,  6.2 (7.6) 6.6 (9.9) 6.3 (8.4)
mean (SD)
n = 413 n = 199 n = 612
Suicide attempts,
n (%) 128 (31.0) 64 (32.2) 192 (31.4)
1 68 (53.1) 32 (50.0) 100 (52.1)
$2 60 (46.9) 32 (50.0) 92 (47.9)
Current tobacco use, yes, n (%) 240 (58.0) 115 (57.5) 355 (57.8)
History of alcohol/drug use, yes, n (%) 124 (30.0) 59 (29.5) 183 (29.8)
Alcohol 79 (63.7) 42 (71.2) 121 (66.1)
Cocaine 56 (45.2) 30 (50.9) 86 (47.0)
Marijuana 63 (50.8) 25 (42.4) 88 (48.1)
Otherb 26 (21.0) 10 (17.0) 36 (19.7)
PANSS score, mean (SD)
Total 93.3 (13.2) 91.6 (12.3) 92.8 (13.0)
Positive symptoms 27.4 (5.3) 27.1 (5.0) 27.3 (5.2)
Negative symptoms 18.8 (6.2) 18.2 (5.9) 18.6 (6.1)
Anxiety/depression 13.2 (3.7) 12.9 (3.9) 13.1 (3.7)
Disorganized thoughts 19.7 (4.2) 19.3 (4.0) 19.6 (4.1)
Hostility/uncontrolled excitement 14.2 (3.0) 14.1 (3.1) 14.2 (3.0)
CGi-S-SCA, mean (SD)
Total score 4.6 (0.6) 4.6 (0.6) 4.6 (0.6)
Positive domain 4.5 (0.7) 4.5 (0.7) 4.5 (0.7)
Negative domain 3.3 (1.1) 3.2 (1.1) 3.2 (1.1)
Depressive domain 3.2 (1.5) 3.2 (1.5) 3.2 (1.5)
Manic domain 3.5 (1.5) 3.5 (1.6) 3.5 (1.5)
YMRS, mean (SD) 24.6 (10.1) 24.2 (10.1) 24.4 (10.0)
HAM-D-21, mean (SD) 20.4 (9.0) 19.6 (8.3) 20.1 (8.8)
YMRS $ 16, n (%) 328 (79.2) 160 (80.0) 488 (79.5)
HAM-D-21 $ 16, n (%) 282 (68.1) 129 (64.5) 411 (66.9)
YMRS and HAM-D-21 $ 16, n (%) 196 (47.3) 89 (44.5) 285 (46.4)
Notes: aData are not mutually exclusive; bOther includes heroin, depressants, mixed substance use, and other compounds.
Abbreviations: BMi, body mass index; CGi-S-SCA, Clinical Global impressions of Severity for Schizoaffective Disorder; eR, extended-release; HAM-D-21, 21-item Hamilton 
Rating Scale for Depression; PANSS, Positive and Negative Syndrome Scale; SCA, schizoaffective disorder; SD, standard deviation; YMRS, Young Mania Rating Scale; y, years.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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and domain scores, were greater with paliperidone ER than 
with placebo (Table 3). Results using a repeated-measures 
linear model were consistent with those of the LOCF analy-
sis (Table 3). Composite response rates were higher with 
paliperidone ER (50%) than with placebo (35%, P , 0.001, 
Figure 4).
Paliperidone ER alone or adjunctive 
to mood stabilizers and/or 
antidepressants
Approximately one half of the population was receiving 
mood stabilizers and/or antidepressants at baseline and 
continued these medications during the study, which 
allowed examination of the efficacy of paliperidone 
ER with or without mood stabilizers and/or antidepres-
sants. Mean (SD) PANSS total scores at baseline were 
similar for subjects in both groups at 93.1 (13.0) for 
subjects receiving paliperidone ER as monotherapy 
and 93.5 (13.6) in those receiving paliperidone ER 
adjunctive to mood stabilizers and/or antidepressants. 
Improvement at the six-week endpoint was greater 
with paliperidone ER than with placebo in both groups   
(Figure 3).
Table 2 Specific medications used by subjects in the adjunctive 
mood stabilizers and/or antidepressants group (n = 275)
Medications n (%)
Mood stabilizers 191 (69)
valproic acid 140 (51)
Lithium 43 (16)
Lamotrigine 6 (2)
Antidepressants 135 (49)
escitalopram 26 (9)
Sertraline 22 (8)
venlafaxine 18 (7)
Fluoxetine 16 (6)
Trazodone 16 (6)
Bupropion 13 (5)
Amitriptyline 8 (3)
Mirtazapine 7 (3)
Paroxetine 7 (3)
Duloxetine 6 (2)
Citalopram 5 (2)
Othera 11 (4)
Note: aOther includes tianeptine, imipramine, clomipramine, dosulepin, fluvoxamine, 
and mianserin.
the study endpoint: placebo-adjusted least-squares mean 
  (standard error) difference at LOCF endpoint (paliperidone 
ER minus placebo), −7.8 (1.7); P , 0.001 (Figures 2 and 3). 
The effect size was 0.41. Improvements on other measures, 
including the PANSS   factor scores and CGI-S-SCA total 
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Figure 2 Mean PANSS total score over time (intent-to-treat analysis set).
Notes: Analysis is based on an ANCOVA model with fixed effects for treatment, study, country nested within study, and the baseline value as a covariate. aP , 0.05, 
paliperidone eR versus placebo; bP , 0.01, paliperidone eR versus placebo.
Abbreviations: ANCOvA, analysis-of-covariance; BL, baseline; eR, extended-release; LOCF, last-observation-carried-forward; PANSS, Positive and Negative Syndrome 
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Overall population
Monotherapy
Adjunctive with MS/ADs
YMRS ≥16 at baseline
HAM-D-21 ≥16 at baseline
YMRS and HAM-D-21 ≥16 
at baseline
YMRS <16 at baseline
HAM-D-21 <16 at baseline
−7.8 (95% Cl: −11.0, −4.6)a
−9.2 (95% Cl: −14.0, −4.8)a
−8.2 (95% Cl: −12.0, −4.5)a
−7.5 (95% Cl: −15.0, −0.4)b
−7.9 (95% Cl: −12.0, −3.8)a
−7.6 (95% Cl: −13.0, −1.9)b
−8.5 (95% Cl: −13.0, −3.4)a
−6.0 (95% Cl: −11.0, −1.3)b
Paliperidone ER
(n)
Placebo
(n)
228
414 200
111
186 89
328 160
80 46
282 129
132 71
196 89
−16− 14 −12− 10 −8 −6 −4 −2 0 2
LS mean difference in PANSS total score
Favors treatment Favors placebo
Figure 3 Adjusted mean differences and 95% Cis for PANSS total change scores at endpoint with paliperidone eR versus placebo (intent-to-treat analysis set).
Notes: Analysis is based on an ANCOVA model with fixed effects for treatment, study, country nested within study, and the baseline value as a covariate. aP # 0.001, 
paliperidone eR versus placebo; bP , 0.05, paliperidone eR versus placebo.
Abbreviations: CI, confidence interval; ER, extended-release; HAM-D-21, 21-item Hamilton Rating Scale for Depression; LS, least-squares; MS/ADs, mood stabilizers/
antidepressants; PANSS, Positive and Negative Syndrome Scale; YMRS, Young Mania Rating Scale.
Table 3 Efficacy results for the pooled population (n = 614)a 
Parameter, change 
from baseline
Week 6 (LOCF) endpoint, ANCOVA Week 6 repeated-measures, ANCOVA
Paliperidone ER Placebo Paliperidone ER Placebo
PANSS scores, LS mean (SE) n = 414 n = 200 n = 278 n = 115
Total −26.2 (1.1)b −18.3 (1.5) −28.5 (1.1)b −21.5 (1.6)
Positive factor −8.0 (0.4)b −5.7 (0.5) −8.8 (0.4)c −6.7 (0.5)
Negative factor −4.0 (0.3)b −2.6 (0.4) −4.3 (0.3)d −3.2 (0.4)
Anxiety/depression −4.2 (0.2)c −3.3 (0.3) −4.5 (0.2)d −3.8 (0.3)
Disorganized thoughts −4.6 (0.3)b −3.0 (0.3) −5.2 (0.3)c −3.8 (0.4)
Uncontrolled hostility/excitement −5.4 (0.2)b −4.0 (0.3) −6.1 (0.2)b −4.7 (0.3)
CGI-S-SCA, LS mean (SE) n = 413 n = 200 n = 277 n = 115
Overall −1.5 (0.1)b −1.0 (0.1) −1.7 (0.1)c −1.3 (0.1)
Positive domain −1.5 (0.1)b −1.0 (0.1) −1.8 (0.1)c −1.4 (0.1)
Negative domain −0.7 (0.1)c −0.5 (0.1) −0.8 (0.1) −0.6 (0.1)
Depressive domain −0.9 (0.1)b −0.6 (0.1) −1.0 (0.1)c −0.7 (0.1)
Manic domain −1.2 (0.1)b −0.9 (0.1) −1.3 (0.1)d −1.0 (0.1)
Subjects with YMRS $ 16 n = 328 n = 160 n = 219 n = 93
YMRS total, LS mean (Se) −14.6 (0.7)b −9.8 (0.9) −16.1 (0.7)b −11.0 (1.0)
Subjects with HAM-D-21 $ 16 n = 282 n = 129 n = 178 n = 70
HAM-D-21 total, LS mean (Se) −12.7 (0.7)b −8.9 (0.9) −14.0 (0.6)c −10.9 (0.9)
Notes: The repeated-measures mixed-effects ANCOVA model included the baseline score as a fixed-effect covariate; treatment, concomitant medication stratum, country, 
study, country nested within study, and time (scheduled visit assessment) as fixed-effect (categoric) factors; and treatment by visit interaction. The correlation of the repeated 
measures is modeled with an unstructured covariance matrix. aThe LOCF analysis is based on an ANCOVA model with fixed effects for treatment, study, country nested 
within study, and the baseline value as a covariate; bP # 0.001, paliperidone eR versus placebo; cP , 0.01, paliperidone eR versus placebo; dP , 0.05, paliperidone eR vs 
placebo.
Abbreviations: ANCOvA, analysis-of-covariance; CGi-S-SCA, Clinical Global impressions-Severity-Schizoaffective Disorder; eR, extended-release; LS, least-squares; 
HAM-D-21, 21-item Hamilton Rating Scale for Depression; LOCF, last-observation-carried-forward; PANSS, Positive and Negative Syndrome Scale; Se, standard error; 
YMRS, Young Mania Rating Scale.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Subjects with prominent manic, 
depressive, or mixed symptoms
The size of the pooled population allowed for additional 
subgroup analyses based on the prominence of baseline 
affective symptoms (subjects with YMRS and/or HAM-
D-21 score $ 16 at baseline). PANSS total scores improved 
significantly more with paliperidone ER than with placebo 
in each of these groups at endpoint (Figure 3).
Further analyses of these subgroups examined the effect 
of paliperidone ER on mood symptoms. Improvements 
in YMRS and HAM-D-21 were greater with paliperidone 
ER than with placebo, as measured by placebo-adjusted 
least-squares mean (95% CI) changes from baseline of −4.8 
(−6.8, −2.9) and −3.8 (−5.5, −2.0), respectively. Both YMRS 
and HAM-D-21 scores improved with paliperidone ER as 
monotherapy or as adjunctive therapy with mood stabilizers 
and/or antidepressants (Figure 5).
Tolerability
The most frequent adverse events ($5.0% in paliperidone ER 
subjects) among subjects receiving paliperidone ER versus 
placebo were headache (14.3% versus 14.9%), tremor (8.1% 
versus 3.5%), dizziness (6.7% versus 5.9%), insomnia (6.7% 
versus 6.9%), nausea (6.4% versus 5.9%), akathisia (5.5% 
versus 4.5%), hypertonia (5.5% versus 2.0%), dyspepsia 
(5.5% versus 2.5%), somnolence (5.2% versus 2.0%), and 
sedation (5.0% versus 3.5%). An analysis of RR found a 
greater risk of tremor with paliperidone ER than with placebo 
(RR = 2.34; 95% CI = 1.05, 5.18, Figure 6). Significance for 
increased risk (defined as the 95% CI not including 1) of the 
other adverse events was not observed.
The overall adverse event rate was higher in subjects 
who received paliperidone ER as adjunctive therapy to mood 
stabilizers and/or antidepressants (70.4%, paliperidone ER; 
70.0%, placebo) than in those who received paliperidone ER 
as monotherapy (60.5%, paliperidone ER; 49.1%, placebo). 
An analysis of RR found a greater risk of tremor with pali-
peridone ER than with placebo (RR = 4.38; 95% CI = 1.04, 
18.56) in the monotherapy group (Figure 6). Significance 
for increased risk of adverse events was not observed in the 
mood stabilizer and/or antidepressant group.
The percentage of discontinuations due to adverse events 
was similar for both the paliperidone ER- and the placebo-
treated groups (each 7%) but was slightly higher in the group 
receiving paliperidone ER adjunctive to mood stabilizers 
and/or antidepressants (8.2%) than in the group receiving 
paliperidone ER as monotherapy (5.0%).
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Adverse events of particular relevance with antipsychotic 
therapy are extrapyramidal symptoms, weight and metabolic 
changes, and prolactin elevation. Extrapyramidal symptoms 
were reported in 19.8% of subjects receiving paliperidone 
ER and in 10.9% of those receiving placebo. The severity 
of extrapyramidal symptoms as measured using the SAS, 
AIMS, and BAS was low (global score , 1) in both groups 
at baseline and endpoint.
At endpoint, mean (SD) changes in prolactin levels 
(ng/mL) were greater with paliperidone ER versus pla-
cebo for both males (12.6 [20.1] versus −3.6 [13.3]) and 
females (51.4 [62.1] versus −13.9 [32.4]). There were 9 
(2.1%) subjects receiving paliperidone ER and one (0.5%) 
subject receiving placebo who experienced a potentially 
  prolactin-related adverse event. The mean (SD) weight 
change was 1.0 (2.7) kg for paliperidone ER and 0.2 (2.1) kg 
for placebo. There were no clinically relevant differences in 
the lipid profile or fasting glucose levels for paliperidone 
ER compared with placebo.
Additionally, no clinically relevant differences were 
found in the incidence of extrapyramidal symptoms or in 
changes in mean weight, lipid profile, fasting glucose level, 
or prolactin level between subjects who received paliperidone 
ER as monotherapy and those who received paliperidone 
ER adjunctive to mood stabilizers and/or antidepressants 
(Table 4).
A. LS mean difference in YMRS change scores in subjects with YMRS ≥ 16 at baseline
LS mean difference in YMRS score
Overall population
Monotherapy
Adjunctive MS/ADs
−4.8 (95% Cl: −6.8, −2.9)a
−5.5 (95% Cl: −8.1, −2.9)a
−3.3 (95% Cl: −6.2, −0.4)b
Paliperidone ER
(n)
Placebo
(n)
328 160
193
135 66
94
−10 −8 −6 −4 −2 02
Favors treatment Favors placebo
B. LS mean difference in HAM-D-21 change scores in subjects with HAM-D-21 ≥ 16 at baseline
LS mean difference in HAM-D-21 score
Overall population
Monotherapy
Adjunctive MS/ADs
−3.8 (95% Cl: −5.5, −2.0)a
−3.0 (95% Cl: −5.6, −0.5)b
−4.7 (95% Cl: −7.1, −2.2)a
Paliperidone ER
(n)
Placebo
(n)
281 129
147
134 67
62
−8 −6 −4 −2 0 2
Favors treatment Favors placebo
Figure 5 Adjusted mean differences and 95% confidence intervals for total YMRS and HAM-D-21 change scores at endpoint with paliperidone eR versus placebo in patients 
with manic or depressive symptoms at baseline (intent-to-treat analysis set).
Notes: Analysis is based on an ANCOVA model with fixed effects for treatment, study, country nested within study, and the baseline value as a covariate. aP # 0.001, 
paliperidone eR versus placebo; bP , 0.05, paliperidone eR versus placebo.
Abbreviations: CI, confidence interval; ER, extended-release; HAM-D-21, 21-item Hamilton Rating Scale for Depression; LS, least-squares; MS/ADs, mood stabilizers/
antidepressants; PANSS, Positive and Negative Syndrome Scale; YMRS, Young Mania Rating Scale.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Hypertonia
A.  Overall population
B.  Monotherapy
C.  Adjunctive MS/ADs
Percent Relative risk with 95% Cl
Percent Relative risk with 95% Cl
Percent Relative risk with 95% Cl
Somnolence
Tremor
Dyspepsia
Sedation
Akathisia
Dizziness
Nausea
Insomnia
Headache
1357 1 03 57 91 5
1 03 5791 11 31 5
13579
Placebo (n = 90) Paliperidone ER (n = 190)
Placebo (n = 112) Paliperidone ER (n = 230)
Placebo (n = 202) Paliperidone ER (n = 420)
11 13 19 135791 11 33 7
1 0
0
3579 11 13 15 17 19 53 55
Hypertonia
Somnolence
Tremor
Dyspepsia
Dry mouth
Dizziness
Nausea
Insomnia
Headache
Weight increased
Akathisia
Constipation
Tremor
Agitation
Dizziness
Sedation
Insomnia
Schizoaffective
disorder
Nausea
Headache
Figure 6 Most frequent (in $ 5.0% of paliperidone eR subjects) adverse events sorted by relative risk (safety analysis set) by concomitant medication stratum.
Abbreviations: CI, confidence interval; ER, extended-release; MS/AD, mood stabilizer/antidepressant.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Discussion
To our awareness, this review covers the largest data set of 
patients with schizoaffective disorder, and provides additional 
knowledge of patient characteristics and treatment responses 
to paliperidone ER. Although differential diagnosis across the 
psychosis and mood continuum can be challenging, over 90% 
of subjects carried a chart diagnosis of schizoaffective disorder 
prior to enrollment in the studies. Interestingly, the mean age 
at first schizoaffective disorder diagnosis was approximately 
six years later than the age at first psychiatric diagnosis. This is 
consistent with the longitudinal nature of the diagnosis, which 
requires assessment of the duration of mood symptoms relative 
to the total duration of illness, and suggests that full symptom 
expression emerges over time. All subjects’ diagnoses were 
confirmed by the Structured Clinical Interview for DSM-IV 
Disorders at study entry. Their mean age was approximately 
37 years, with an average of six psychiatric hospitalizations 
per subject, and a previous suicide attempt reported in over 
30% of subjects. These subjects were acutely ill at study entry 
and displayed high levels of concurrent psychotic, manic, and 
depressive symptoms. Notably, approximately one half of this 
population was receiving concomitant mood stabilizers and/or 
antidepressants at baseline.
The data presented here demonstrate that patients with 
schizoaffective disorder can be successfully treated with 
paliperidone ER. Although the mean modal dosage of pali-
peridone ER in these data was 8.6 mg/day, the recommended 
dosage for schizoaffective disorder is 6 mg/day, with a range 
of 3 to 12 mg/day. The dosing recommendation is supported 
by the study designs that utilize this range, and the majority 
of subjects randomized to paliperidone ER were initiated at 
6 mg/day. Additionally, although the lower-dosage group (3 to 
6 mg/day) in the two-dose group study was not superior to 
placebo with regard to PANSS total change, it was associated 
with a significantly higher composite response rate.29
Treatment-emergent adverse events (including extrapy-
ramidal symptom-related adverse events) and changes in 
weight and metabolic parameters that were identified in these 
studies were similar to those found in studies of paliperidone 
ER in schizophrenia.44 As expected, the potent D2 antagonism 
of paliperidone ER compared with other atypical antipsy-
chotics resulted in an elevation in serum prolactin levels, 
with females having a higher increase than males. Of note, 
a previously reported study found that use of paliperidone 
ER resulted in increases in prolactin levels similar to those 
found with the use of risperidone.45
Because patients with schizoaffective disorder are com-
monly treated with antipsychotics and mood stabilizers and/or   Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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antidepressants,26–28 results suggesting that paliperidone ER 
is efficacious both as monotherapy and adjunctive to mood 
stabilizers and/or antidepressants may be particularly valuable 
to the clinician. With the exception of tremor, the tolerability of 
paliperidone ER was comparable when used as monotherapy or 
adjunctive to mood stabilizers and/or antidepressants. However, 
it must be noted that although randomization was stratified by 
mood stabilizer and/or antidepressant use, the study was not 
designed to compare monotherapy with adjunctive therapy or 
to compare the relative efficacy of various adjunctive combi-
nations, and the benefits and risks of specific combinations of 
paliperidone ER and mood stabilizers and/or antidepressants 
have not been studied. Nonetheless, no unique tolerability 
issues were identified with paliperidone ER in this popula-
tion. Because of its limited liability for hepatically mediated 
drug–drug interactions, paliperidone ER may be a useful option 
for patients who follow complex medication regimens.32–34
Several additional factors must be considered in the 
interpretation of these results. First, this study population 
may have been biased toward subjects experiencing manic 
symptoms because of the specified entry criteria. Neverthe-
less, in addition to the 80% of subjects who displayed promi-
nent manic symptoms, 67% of subjects displayed prominent 
depressive symptoms at baseline. Moreover, subjects with 
prominent manic, depressive, or mixed symptoms at baseline 
had significant psychotic and mood symptom improvement 
with paliperidone ER compared with placebo. Finally, long-
term maintenance treatment with paliperidone ER has not 
yet been studied in this population. However, such a trial 
is planned with paliperidone palmitate, the once-monthly 
injectable formulation of paliperidone.
Conclusion
Although schizoaffective disorder is commonly encountered 
in populations of patients with mental illness, this disorder has 
not been methodically studied, and no established guidelines 
exist for the management of these patients. Data pooled from 
two large, international, placebo-controlled, six-week studies 
with paliperidone ER are now available, demonstrating that 
acutely ill patients with schizoaffective disorder manifest 
high levels of psychotic, manic, and depressive symptoms 
at baseline. Patients who received paliperidone ER, either as 
monotherapy or adjunctive to mood stabilizers and/or antide-
pressants, experienced significant improvement in schizoaffec-
tive symptoms. Subjects with prominent manic, depressive, or 
mixed symptoms at baseline showed significant psychotic and 
mood symptom improvement with paliperidone ER compared 
with placebo. Additionally, no new tolerability signals were 
detected in this patient population. These data demonstrate the 
efficacy and tolerability of paliperidone ER as monotherapy 
or adjunctive to mood stabilizers and/or antidepressants in the 
acute treatment of schizoaffective disorder.
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